Company profileNeuromodulation
BrainQ
A wearable device that applies frequency-tuned electromagnetic fields in the weeks after a stroke, to reduce disability.
- Location
- Jerusalem, Israel
- Class
- NeuromodulationA non-invasive stimulation therapy. Its published trial and one registry entry call the device BCI-based. What they describe is a field applied from outside the body, and none describes reading the patient's brain during treatment. It is not counted as a BCI company.Not counted among core BCI companies.
- Also known as
- BrainQ Technologies Ltd. · BRAIN.Q · BrainQ Technologies
- Website
- brainqtech.com
- Sources last checked
- 6 Oct 2026
What they are building
Israeli company, described in its later releases as US-Israeli. Its therapy is delivered by a wearable, cloud-connected device used daily at home after a moderate to severe ischaemic stroke. It has run registered studies in stroke and spinal cord injury since 2018.
- Invasiveness
- Non-invasive
- Recording / stimulation
- Stimulation
- Main use cases
- Restore, Move
Where they are clinically
Pivotal
The trial designed to support a marketing application.
EMAGINE, a double-blind, sham-controlled trial at 15 US centres, was stopped early after 100 of a planned 150 participants, when an interim analysis did not reach the threshold to continue. The published result: disability at 90 days improved numerically more with active stimulation, a difference that did not reach statistical significance. A second trial, EMAGINE 2.0, is recruiting. An FDA Breakthrough designation is not a clearance. The city shown is from trade reporting we found through search; the company's releases say only Israel.
Access today
Clinical study
Accessible only by enrolling in a registered clinical study.
- Shown in people
- A double-blind, sham-controlled trial in 100 patients, published in 2025: disability at 90 days improved numerically more with active stimulation, and the difference was not statistically significant.
- Still an aim
- Authorisation as a stroke therapy, for which EMAGINE 2.0 is recruiting 122 participants.
- What stands in the way
- Efficacy: the first controlled trial did not show a significant benefit on its primary endpoint. The second has to.
On record here: 0 peer-reviewed papers
This technology remains experimental and is not an established treatment. Access is limited to registered clinical studies.
- 11 Feb 2021US FDA — Breakthrough Device designation. A designation speeds interaction with the regulator. It is not a clearance or approval, and the device is a stimulation therapy, not a BCI.
Why this company matters
BrainQ sits at the edge of this field and is here because its own registry entries use the term BCI. What it tests is whether an electromagnetic field applied at home for weeks changes recovery after stroke. The idea asks little of the patient and a great deal of the evidence: the first pivotal trial was stopped early, and its published result did not reach statistical significance on the primary endpoint, though the company had announced it as offering hope. A second trial is under way. Until one succeeds, the effect is unproven.
Key milestones
1 Oct 2025
EMAGINE is published: stopped early at 100 of 150 planned participants; the difference in disability at 90 days favoured active stimulation and was not statistically significant.
20 Aug 2024
EMAGINE 2.0 begins recruiting; 122 participants planned.
16 May 2024
Company announces EMAGINE results at a stroke congress: treated patients were, in its words, more than twice as likely to be free from disability at three months.
4 Dec 2021
EMAGINE begins at US centres. It enrols 100 participants.
11 Feb 2021
FDA Breakthrough Device designation, according to the company.
4 Sep 2018
A study in acute stroke begins in New Delhi. It is later terminated with 28 participants.
Competitive context
EEGApproved / cleared
g.tec medical engineering
An Austrian maker of complete BCI systems and of the amplifiers much of the field's research is recorded with, in business since 1999.
EEGApproved / cleared
Kandu
Maker of IpsiHand, a non-invasive BCI for hand rehabilitation after stroke that the FDA authorised for marketing in 2021, years before any implanted system.
ECoGFeasibility
Motif Neurotech
A miniature, wirelessly powered brain stimulator for treatment-resistant depression.
Sources
- 01
Peer reviewedJAMA Network Open1 Oct 2025Checked against source 6 Oct 2026
DOI 10.1001/jamanetworkopen.2025.37880. Read from the PubMed abstract: double-blind, sham-controlled, 15 US sites, target 150, stopped early at 100 when an interim analysis of 78 did not reach the threshold to continue; primary end point, change in modified Rankin Scale to day 90. The abstract itself calls the device brain-computer interface-based.
- 02
Company reportedBRAIN.Q (press release)16 May 2024Checked against source 6 Oct 2026
The company's account of results presented at a stroke congress. It says the results suggested less disability in treated patients and reports adherence and safety. It gives no statistical test of the primary endpoint.
- 03
Company reportedBrainQ (press release)11 Feb 2021Checked against source 6 Oct 2026
The company's release. It dates the designation to February 2021 and calls the company an Israel-based start-up.
- 04
Clinical registryClinicalTrials.govChecked against source 5 Oct 2026
Sponsor BrainQ Technologies Ltd. Completed with 100 participants; started 4 December 2021.
- 05
Clinical registryClinicalTrials.govChecked against source 5 Oct 2026
Sponsor BrainQ Technologies Ltd. Recruiting since 20 August 2024; 122 participants planned.
- 06
Clinical registryClinicalTrials.govChecked against source 5 Oct 2026
Sponsor BrainQ Technologies Ltd. Terminated with 28 participants; New Delhi; started 4 September 2018. The registry title itself calls the device BCI-based.